IL6ST and breast carcinoma: In their study of primary breast carcinomas, Karczewska et al. found that 5-year rates of both overall (OS) and disease-free survival (DFS) were significantly higher in the IL6ST-positive (IL6ST+) compared to IL6ST-negative groups (90% vs. 9% and 88% vs. 0%, respectively) [38].